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Efficacy of Liposomal Bupivacaine Infiltration
on theManagement of Total Knee Arthroplasty
Bryan Sakamoto, MD, PhD; Shelly Keiser, PharmD; Russell Meldrum, MD;
Gene Harker, MD, PhD; Andrew Freese, MD
IMPORTANCE Liposomal bupivacaine is a novel extended-duration anesthetic that has
recently been used for local infiltration in total knee arthroplasty (TKA). Athough liposomal
bupivacaine is widely used, it is unknown if the benefits justify the cost in the veteran
population at our institution.
OBJECTIVE To evaluate a change in practice: the effect of local infiltration of liposomal
bupivacaine on perioperative outcomes in patients undergoing primary TKA.
DESIGN, SETTING, AND PARTICIPANTS A retrospective cohort studywas conducted among
patients who underwent primary TKA at a Veterans Affairs Medical Center before (March 3,
2013-March 2, 2014) and after (March 3, 2014-March 2, 2015) the implementation of
liposomal bupivacaine for local infiltration in TKA.
INTERVENTION Drug utilization evaluation of liposomal bupivacaine for local infiltration
in TKA.
MAIN OUTCOMES ANDMEASURES Use of opioids after discharge from the postanesthesia
care unit.
RESULTS Among 199 patients, those who received liposomal bupivacaine after primary TKA
(mean [SD] age, 65.3 [6.9] years; 93males and 5 females) had a reducedmedian opioid use
in the first 24 hours after surgery compared with those who did not receive liposomal
bupivacaine (mean [SD] age, 64.9 [8.4] years; 95males and 6 females; [intravenous
morphine equivalents, 12.50 vs 22.50mg; P = .001]). The use of patient-controlled analgesia
was also reduced among patients who received liposomal bupivacaine vs those who did not
(49 vs 91; P < .001). A reduction in the use of antiemetics was observed in the first 24 hours
after surgery (13 vs 34; P = .001) and in the postanesthesia care unit among those who
received liposomal bupivacaine vs those who did not (4 vs 20; P = .001). The number of
patients in the postanesthesia care unit with no pain was improved among those who
received liposomal bupivacaine vs those who did not (44 vs 19; P < .001). Althoughmedian
(interquartile range) pain scores in the postanesthesia care unit were improved among
patients who received liposomal bupivacaine vs those who did not (4.0 [0.0-6.6] vs 5.5
[3.0-7.5]; P = .001), patients who received liposomal bupivacaine had greater median
(interquartile range) pain scores 48 hours (5.5 [4.0-7.0] vs 5.0 [3.0-6.0]; P = .01), 72 hours
(5.0 [4.0-6.0] vs 4.0 [2.0-6.0]; P = .002), and 96 hours (5.0 [3.0-6.5] vs 4.0 [1.0-5.0];
P = .003) after surgery than those who did not receive liposomal bupivacaine. There was no
difference in themedian length of stay between the 2 groups. Institutional cost savings was
estimated at $27000 per year.
CONCLUSIONS AND RELEVANCE Local infiltration of liposomal bupivacaine reduces use of
opioids in the first 24 hours after primary TKA. Similarly, reduction in antiemetic use and
improved postoperative pain are also seen in the first 24 hours after surgery but are limited
to this time frame. Furthermore, a positive institutional cost savings was observed.
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A s thenumber of patients undergoing total knee arthro-plasty (TKA) increases, the search for ways to im-prove outcomes also increases. Adequate pain con-
trol is associated with improved early mobilization and
participation with physical therapy following joint replace-
ment surgery. This mobilization leads to an overall shorter
length of stay in the hospital and reduction in postoperative
complications.1,2
Multimodal or balanced analgesic techniques involving
the use of smaller doses of opioids in combination with
nonopioid analgesic drugs are becoming increasingly
popular approaches to preventing pain after surgery.3
Multimodal analgesia strategies are recognized as effective
methods for improving postoperative pain management
while minimizing opioid-associated adverse effects,4 which
include ventilatory depression, drowsiness and sedation,
postoperative nausea and vomiting, pruritus, urinary reten-
tion, ileus, and constipation, which can delay hospital dis-
charge and lead to unanticipated hospital admissions.5 Mul-
timodal analgesic strategies reduce these adverse effects,
and, as a result, patients mobilize more quickly and are dis-
charged from the hospital earlier.1,6-8 In addition, it has been
suggested by the Joint Commission that excessive use of
postoperative opioid analgesics leads to decreased patient
satisfaction.3
The multimodal approach uses many delivery systems,
including oral agents, epidural catheters, peripheral nerve
blocks, and periarticular injection (PAI). Research suggests
that PAI provides postoperative pain scores comparable
with those achieved with epidural catheters and femoral
nerve blocks, with a lower risk of quadriceps weakness and
systemic adverse effects.9,10 These advantages of PAI allow
patients to mobilize more quickly and reduce the risk of fall-
ing, leading to improved participation with therapy and
patient satisfaction.9,11
Liposomal bupivacaine is a novel formulation of bupiva-
caine approved by the US Food and Drug Administration for
local infiltration of surgical sites to produce extended post-
surgical analgesia. It has recently emerged as a popular
option for PAI because its therapeutic effects last up to 72
hours.12,13 Furthermore, its use was associated with an over-
all decrease in use of narcotics by patients undergoing total
joint arthroplasty.13 Previous studies have established the
safety and efficacy of liposomal bupivacaine, and there has
been no evidence of increased adverse effects or outcomes
in comparison with bupivacaine hydrochloride.13-17
Several small studies have shown improved pain scores,
decreased use of narcotics, and shorter length of stay fol-
lowing total joint arthroplasty with the use of liposomal
bupivacaine PAI.8,11 Although liposomal bupivacaine is
more expensive than alternative PAI agents (eg, bupivacaine
and ropivacaine hydrochloride), it has recently gained favor
at the Richard L. Roudebush Veterans Affairs Medical Center
for TKA surgery. The main purpose of this medication use
study is to evaluate the cost vs benefit of using this agent in
our veteran patient population. To our knowledge, this is
the first study to evaluate the use of liposomal bupivacaine
in TKA in the Veterans Affairs medical system.
Methods
Study Design
A single-center, 2-year, retrospective cohort study was per-
formed to evaluate the effect of PAI of liposomal bupiva-
caine on postoperative use of narcotics, as well as other
patient clinical outcomes, in patients undergoing elective
TKA. This interperiod study evaluated patient clinical out-
comes before (March 3, 2013-March 2, 2014) and after
(March 3, 2014-March 2, 2015) the implementation of a
change in practice: the addition of PAI of liposomal bupiva-
caine in patients undergoing TKA. All procedures were per-
formed by a single staff surgeon (R.M.) at the Richard L.
Roudebush Veterans Affairs Medical Center. Only patients
undergoing elective primary total joint arthroplasty were
included. Patients who underwent a revision of prior TKA,
unicompartmental knee arthroplasty, or bilateral arthro-
plasty and those who did not receive a femoral or adductor
canal nerve block were excluded from the analysis. Other
data collected included patient’s age, sex, height, weight,
body mass index, American Society of Anesthesiologists
Risk Index scores, presence of chronic pain (use of opioids
for >3 months), and tobacco use. The use of these data con-
forms with the Health Insurance Portability and Account-
ability Act of 1996 confidentiality requirements. In addition,
because this project was a retrospective medical record
review and quality improvement study, approval and
informed patient consent were not required by the Indiana
University Institutional Review Board and the Richard L.
Roudebush Veterans Affairs Medical Center.
PatientsWho Received a PAI
Using a modified version of the technique described by
Guild et al,18 20 mL of 1.3% liposomal bupivacaine (266 mg)
was diluted with injectable saline to a total volume of
40 mL. A 20-mL syringe with a 1.2 × 40-mm needle was
used to administer the liposomal bupivacaine solution. After
negative aspiration of blood, 2 to 5 mL of the bupivacaine
solution was injected into the superficial and deep layers of
the surgical field. Injection of the superficial layer was per-
formed by staying on the edges of the operative field work-
ing toward the middle of the surgical field. The tip of the
Key Points
Question Do the benefits justify the cost of liposomal bupivacaine
for local infiltration in total knee arthroplasty in a veteran
population?
Findings In a drug utilization evaluation, patients undergoing
total knee arthroplasty with liposomal bupivacaine had a reduced
median use of opioids in the initial 24 hours after surgery, as well
as a reduction in the use of patient-controlled analgesia and
antiemetics. An institutional cost savings was estimated at
$27000 per year.
Meaning The results of this drug utilization evaluation support
the use of local infiltration of liposomal bupivacaine in total knee
arthroplasty.
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needle was placed deep to the muscle’s fascial layers during
these injections. In the deep layer, the bupivacaine solution
was injected into the extracapsular space through the deep
posterior knee capsule and into the popliteal fossa. The tip
of the needle was placed through the capsule until resis-
tance was lost. The superficial and deep injections of the
knee were performed before cementing of the implants.
Pain Control Regimen
Patients undergoing TKAwere prescribed the following stan-
dardpain control regimen: oral hydrocodonebitartrate, 5mg,
with acetaminophen, 325 mg, or oxycodone hydrochloride,
5mg,with acetaminophen, 325mg, every 4hourswith an ad-
ditional tablet every4hours asneeded.Forpain that couldnot
be controlled by oral opiates, the patients were additionally
offered intravenous morphine sulfate, 2 to 4 mg, or hydro-
morphonehydrochloride0.5 to1.0mgevery4hoursasneeded.
For the first 24 hours, morphine or hydromorphone patient-
controlled analgesia (PCA)was offered for pain that could not
be controlled by oral and intravenous opiates (at the begin-
ningof the studyperiod, PCAwas scheduledaspart of the rou-
tine admitting orders, but after the change in practice, they
were ordered on an as-neededbasis because patientswere no
longer routinely using them). Before surgery, if a patient was
taking long-acting oral opiates, these medications were re-
sumed as needed for breakthrough pain as described above.
Intravenousketorolac tromethamine, 15mg,every6hourswas
also prescribed if renal function was within normal limits
(owing to a national drug shortage, ketorolacwas unavailable
for 1 year that overlapped both arms of this study). On admis-
sion, homepainmedicationswere also resumed,which could
includemultimodal options such as gabapentin andpregaba-
lin.Oralhydroxyzinepamoate, 25mg, every6hours asneeded
was available for itching and/or pain.
OutcomeMeasures
The primary outcomewas opioid use (intravenousmorphine
equivalents) after discharge fromthepostanesthesia careunit
(PACU).Secondaryoutcomes includedperioperativeandPACU
opioiduse, averagepostoperativepain scores in thePACUand
surgical ward (numeric rating scale from0 to 10), use of PCA,
use of naloxone in the PACU and surgical ward, use of anti-
emetic medications in the PACU and surgical ward, and days
todischarge.Acost analysiswas completedcomparing theuse
of liposomal bupivacainewith the institution’s standardpost-
operative pain regimen before this change in practice.
Statistical Analysis
Continuous variables are reported asmean (SD) and analyzed
using a 2-tailed t test. Categorical data are compared using a
χ2 test and relative risk analysis. Pain scores, use of opioids,
and length of stay are reported asmedians. The 25th and 75th
percentiles are includedas indicators of variability (interquar-
tile range).Differences inpainscores,useofopioids, and length
of stay were tested using theMann-Whitney test. P < .05was
consideredsignificant.Statistical analysiswasperformedusing
SPSS, version 22 (IBM Corp).
Results
A total of 217 patients who had an elective primary TKAwere
studied (101 patients before the change in practice and 98 pa-
tients after the change in practice; 18 patients were ex-
cluded).Analysis of thedemographicdata (Table 1) shows that
the 2 groups arewellmatched except for American Society of
Anesthesiologists Risk Index scores (P = .02).
PatientsundergoingprimaryTKAafter the change inprac-
tice (useof liposomal bupivacaine) hada reducedmedianopi-
oiduse (intravenousmorphineequivalents) in the first24hours
after surgery compared with those who underwent TKA be-
fore the change in practice (12.50 vs 22.50 mg; P = .001). No
difference in median opioid use was observed in the 48 and
96 hours following surgery. However, there was an increase
in median opioid use 72 hours after surgery among patients
who received liposomal bupivacaine vs those who did not
(20.00vs 15.00mg;P = .003;Table 2). Although therewasno
difference in perioperative use of fentanyl between the 2
groups, median perioperative use of opioids was signifi-
cantly reduced in the liposomal bupivacaine group (5.33 mg)
compared with those who did not receive liposomal bupiva-
caine (6.67mg), aswasmedianuseofopioids in thePACU(2.67
vs 6.00mg; Table 3). No naloxonewas administered in either
group in the PACU. In addition, therewas no statistical differ-
ence in naloxone administration on the surgical ward
between the 2 groups (Table 4).
Althoughmedian verbal pain scores in the PACUwere im-
proved inthe liposomalbupivacainegroupvsthosewhodidnot
receive liposomal bupivacaine (4.0 vs 5.5; P = .001) (Table 3),
Table 1. Patient Demographics
Characteristic
No Liposomal
Bupivacaine
(n = 101)
Liposomal
Bupivacaine
(n = 98) P Valuea
Age, mean (SD), y 64.9 (8.4) 65.3 (6.9) .70
Sex
Male 95 93 .80
Female 6 5
Weight, mean (SD), kg 111.40 (24.88) 108.47 (25.39) .41
Height, mean (SD), cm 176.60 (8.10) 176.48 (7.40) .91
BMI, mean (SD) 35.74 (7.68) 34.50 (7.07) .24
ASA Risk Index score
2 1 8
.02b
3 100 90
Chronic pain
(opioids >3 mo)
Yes 46 40
.50
No 55 58
Tobacco use
Yes 29 24
.50
No 72 74
Abbreviations: ASA, American Society of Anesthesiologists; BMI, bodymass
index (calculated as weight in kilograms divided by height in meters squared).
a Age, weight, height, and BMI are compared using t test. Sex, ASA Risk Index
score, chronic pain, and tobacco use are compared using χ2 test. All P values
are 2-tailed.
b Statistically significant.
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those who received liposomal bupivacaine had greater me-
dianpainscores48 (5.5vs5.0;P = .01), 72 (5.0vs4.0;P = .002),
and 96 (5.0 vs 4.0; P = .003) hours after surgery (Table 2). The
number of patients with no pain in the PACUwas improved in
the liposomal bupivacaine group vs thosewho did not receive
liposomalbupivacaine (44vs 19;P < .001; absolute relative risk
[ARR],0.26;95%CI,0.25-0.27) (Table3andTable5).Therewas
a139%relativeriskreductionofpatientshavingpaininthePACU
when treatedwith liposomal bupivacaine (Table 5). The num-
berneeded to treatwas3.8 (95%CI, 3.7-4.0), indicating that for
every 3.8 patients treated with liposomal bupivacaine,
1 patient will have no pain in the PACU (Table 5).
A reduction in antiemetic use in the liposomal bupiva-
caine group vs those who did not receive liposomal bupiva-
caine was observed in the first 24 hours after surgery (13 vs
34; P = .001; ARR, 0.20; 95% CI, 0.16-0.24) (Tables 4 and 5)
and in the PACU (4 vs 20; P = .001; ARR, 0.16; 95% CI, 0.16-
0.16) (Tables 3 and 5). There was a 61% and 72% relative risk
reduction of patients requiring an antiemetic in the first 24
hours after surgery and in the PACU when treated with lipo-
somal bupivacaine, respectively (Table 5). The number
needed to treat was 5.0 (95% CI, 4.2-6.3) and 6.4 (95% CI,
6.4-6.4), indicating that for every 5.0 and 6.4 patients
treated with liposomal bupivacaine, 1 patient will require an
antiemetic in the first 24 hours after surgery and in the
PACU, respectively (Table 5). The use of PCA was reduced in
the liposomal bupivacaine group vs those who did not
receive liposomal bupivacaine (49 vs 91; P < .001; ARR,
0.40; 95% CI, 0.39-0.41) (Tables 4 and 5). There was a 45%
relative risk reduction of patients requiring PCA when
treated with liposomal bupivacaine (Table 5). The number
needed to treat was 2.5 (95% CI, 2.4-2.6), indicating that for
every 2.5 patients treated with liposomal bupivacaine,
1 patient will require PCA (Table 5). There was no difference
in the median length of stay between the 2 groups (Table 2).
Table 2. Total Opioid Use, Pain Scores, and LOS
Characteristic
No Liposomal
Bupivacaine
Patients,
No.a
Liposomal
Bupivacaine
Patients,
No.a P Valueb
Total opioids, median (IQR), hc
24 22.50 (12.25-36.00) 101 12.50 (7.50-29.48) 98 .001d
48 24.00 (18.70-29.00) 101 25.00 (20.00-32.63) 98 .07
72 15.00 (12.50-22.88) 92 20.00 (15.00-30.50) 91 .003d
96 15.00 (10.00-20.00) 43 15.00 (10.00-25.10) 46 .97
Pain scores, median (IQR), h
24 5.0 (3.0-6.0) 101 4.0 (2.8-6.0) 98 .46
48 5.0 (3.0-6.0) 101 5.5 (4.0-7.0) 98 .01d
72 4.0 (2.0-6.0) 92 5.0 (4.0-6.0) 91 .002d
96 4.0 (1.0-5.0) 43 5.0 (3.0-6.5) 45 .003d
LOS, median (IQR), d 3.0 (3.0-4.0) 101 3.0 (3.0-4.0) 98 .80
Abbreviations: IQR, interquartile
range; LOS, length of stay.
a Numbers in the Total opioids and
Pain scores groups decrease as
patients are discharged.
bDifferences in total opioids, pain
scores, and LOSwere analyzed
using theMann-Whitney test.
All P values are 2-tailed.
c Total opioid use presented in
intravenous morphine equivalents.
d Statistically significant.
Table 3. Perioperative and PACUData
Characteristic
No Liposomal
Bupivacaine
(n = 101)
Liposomal
Bupivacaine
(n = 98) P Valuea
Perioperative medication use, median (IQR)
Fentanylb 25 (15-25) 25 (15-25) .97
Opioidsc 6.67 (4.00-9.33) 5.33 (2.67-6.67) .01d
PACU medication use, median (IQR)
Opioidsc 6.00 (2.34-9.33) 2.67 (0.00-6.67) <.001d
Antiemetic use, No.
Yes 20 4
.001d
No 81 94
Pain score, median (IQR) 5.5 (3.0-7.5) 4.0 (0.0-6.6) .001d
Patients with no pain, No.
Yes 19 44
<.001d
No 82 54
Abbreviations: IQR, interquartile
range; PACU, postanesthesia care
unit.
a Differences in fentanyl, opioids, and
pain scores were analyzed using the
Mann-Whitney test. Antiemetics
and patients with no pain were
compared using the χ2 test.
All P values are 2-tailed.
b Fentanyl use was converted to
intravenous morphine equivalents.
c Opioid use was presented in
intravenous morphine equivalents.
d Statistical significance.
Table 4. Antiemetic and Use of Patient-Controlled Analgesia
Characteristic
No Liposomal
Bupivacaine
Liposomal
Bupivacaine
P ValueaYes No Yes No
Patients receiving
antiemetics, hb
24 34 67 13 85 .001c
48 21 80 13 85 .16
72 4 97 5 86 .62
96 0 43 3 43 .09
Use of naloxone 1 100 0 98 .32
Patient-controlled
analgesia
91 10 49 49 <.001c
a Differences in antiemetic, naloxone, and patient-controlled analgesia use were
analyzed using the χ2 test. All P values are 2-tailed.
b The number in the patients receiving antiemetics group decreases as patients
are discharged.
c Statistically significant.
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Discussion
Significantdifferenceswere found inboth theprimaryandsec-
ondary outcomes in patients who received liposomal bupiva-
caine forTKA.Totalopioidusewasdecreasedforupto24hours
after surgery, resulting in nearly a 50%decrease in use of PCA.
In addition, perioperative and PACU opioid use was signifi-
cantly reduced in the liposomal bupivacaine group. Patients’
pain was often adequately controlled with use of oral opioids.
Secondarily, use of antiemetic medication significantly de-
creased inthefirst24hoursafter surgery inpatients in thePACU
and the surgicalward.These results appear to contradict those
ofBagsbyetal,19whoreportednosignificantdifference inmean
use of opioids and antiemetics. They reported that, in the first
24 hours after surgery, mean (SD) opioid use (in morphine
equivalents) for those in the liposomal bupivacaine group
(n = 65) was 6.21 (18.30) mEq and for those in the ropivacaine
group (n = 85) was 13.75 (13.42) mEq (P = .34). Using the pro-
vided values in their article, we calculated P = .004 using a
2-tailed t test, indicating that the liposomal bupivacaine treat-
ment groupused significantly less opioids in the first 24 hours
after surgery than did the ropivacaine group.
Areduction inuseofopioidsdecreases thepotential forad-
verse events such as sedation, respiratory depression, nau-
sea, vomiting, and constipation. Our study shows a signifi-
cant decrease in use of opioids, particularly of intravenous
opioids, in the first 24 hours after surgery among those who
received liposomal bupivacaine, which translates into in-
creased patient safety. One patient in the control group re-
ceived naloxone for sedation reversal vs no patients in the
liposomal bupivacaine group. This result, althoughnot statis-
tically significant,might bedeemedclinically significant. Fur-
thermore, our study demonstrates a decrease in use of anti-
emetics, which equates to less nausea and vomiting and
presumably greater patient satisfaction.
We also observed that significantly more patients in the
liposomal bupivacaine cohort reported no pain in the PACU,
which coincideswith results fromastudybyBarringtonet al,8
who reported that a higher percentage of patients who re-
ceived liposomal bupivacaine reported no pain during their
hospital stay. Pain scores in our studywere also lower among
patients in the PACU; however, this findingwasnot sustained
oncepatientsweremoved to abedon the surgicalward. In ad-
dition, therewasno statistical difference inmedianopioiduse
between the 2 groups at 48 and 96 hours after surgery. How-
ever, therewasastatistically significant increase inmedianopi-
oid use 72 hours after surgery in the liposomal bupivacaine
group (Table 2). Although these effectsmaybe secondary to a
rebound effect of the liposomal bupivacaine injection, itmay
also suggest limited utility of this technique.
Multiple studies report a decreased length of stay for
patients who received liposomal bupivacaine.20-22 Broome
and Burnikel21 noted that 12% of patients who received lipo-
somal bupivacaine were discharged on postoperative day 1
vs none of the patients who received a femoral nerve block.
Berend et al22 reported that more than 98% of patients were
discharged on postoperative day 0 and had a decreased time
in the PACU. In our study, data on patients’ readiness for dis-
charge from the PACU were not collected since nurses only
documented when the patient was discharged from our
PACU. At our institution, for a variety of reasons, a patient
may remain in the PACU despite clinically being ready for
discharge (eg, no bed available and shift change on the
wards). Our study did not show a statistically significant
decrease in length of stay. However, many of our surgical
patients are referred to this facility from other facilities, and
their discharge to home or a rehabilitation facility is depen-
dent on nonmedical issues, such as availability of transpor-
tation and family to help in their care.
Although the intermediate and long-term benefits of li-
posomal bupivacaine were not specifically addressed in our
study, a large retrospective cohort study found that opioid-
sparing regimens may decrease the frequency of opioid-
associated adverse drug events, particularly among high-risk
patients (≥65years,males, obesity,prioropioiduse, andhigher
Charlson Comorbidity Indexes), thereby decreasing overall
cost burden to the hospital system and improving patient
outcomes.23 In our study, the short-term benefits of PAI in-
cluded a significant decrease in opioid consumption 24hours
after surgery, reduction in use of PCA, and less use of anti-
emetics. Reduction in use of opioids has been shown to
increase patient satisfaction3 and safety secondary to a
decrease in opioid-associated adverse events.5
Our study found a decrease in total per-patient cost
based on use of PCA. In the patients who did not receive
PCA, there was a cost savings of approximately $350 per
patient (PCA pump, medication, and carbon dioxide tubing
and monitoring, minus the cost of the medication). Based
on the number needed to treat of 2.5 (Table 5), use of lipo-
somal bupivacaine will result in a savings of approximately
$15 000 per year based on the number of patients in this
study. (Our institutional cost of liposomal bupivacaine was
recently reduced by 50%, which would change the cost sav-
ings to approximately $500 per patient who did not receive
PCA or $27000 per year).
Table 5. Relative Risk
Characteristic
Absolute RR
(95% CI)
RR
Reduction
NNT
(95% CI)
RR of receiving an antiemetic with liposomal bupivacaine
in first 24 h after surgery
0.20 (0.16-0.24) 0.61 5.0 (4.2-6.3)
RR of receiving an antiemetic in the PACU
with liposomal bupivacaine
0.16 (0.16-0.16) 0.72 6.4 (6.4-6.4)
RR of receiving PCA with liposomal bupivacaine 0.40 (0.39-0.41) 0.45 2.5 (2.4-2.6)
RR of no pain in the PACU with liposomal bupivacaine 0.26 (0.25-0.27) 1.39 3.8 (3.7-4.0)
Abbreviations: NNT, number needed
to treat; PACU, postanesthesia care
unit; PCA, patient-controlled
analgesia; RR, relative risk.
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This study has several limitations, including retrospec-
tive design, lack of standardization of recording pain scores,
and variations in postoperative adjunctive pain medications
(ketorolac, celecoxib, acetaminophen, and ibuprofen). In ad-
dition, once the change in practice occurred, all patients still
received PCA until the nurses were informed of the change,
atwhichpointPCAwasprescribedonanas-neededbasis. This
delay in change probably led to additional PCA given to pa-
tients in the liposomal bupivacaine group and underesti-
mated the true cost savings.
Conclusions
The results of this drug utilization evaluation support the use
of local infiltration of liposomal bupivacaine in primary TKA
surgery at this institution. Specifically, there was a reduction
in use of opioids in the first 24 hours and the need for PCA af-
ter surgery. Inaddition,useof antiemeticsdecreasedandpost-
operative pain improved in the first 24 hours after surgery.
Finally, a positive institutional cost savings was appreciated.
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